Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23393800 | 0.82 | ALDH1A1 (0.39) | APPALDH1A1TRPA1TSHRMAOA | |
| SCHEMBL23536313 | 0.81 | DAO (0.40) | APPTSHRMAOAMAOBSLC6A4 | |
| SCHEMBL1684523 | 0.78 | MAOA (0.48) | ALDH1A1MAOAMAOBSMN1; SMN2 | |
| SCHEMBL8881477 | 0.76 | KDM4E (0.42) | ALDH1A1TSHRKDM4E | |
| SCHEMBL24894090 | 0.74 | CYP3A4 (0.44) | ALDH1A1TSHRMAOAKDM4E | |
| SCHEMBL12557496 | 0.74 | KDM4E (0.32) | APPALDH1A1MAOASLC6A4KDM4E | |
| SCHEMBL2647401 | 0.73 | CA2 (0.47) | ALDH1A1TSHRKDM4E | |
| SCHEMBL942119 | 0.73 | ALDH1A1 (0.52) | ALDH1A1TSHRMAOAMAOBSMN1; SMN2 | |
| SCHEMBL10731219 | 0.72 | ALDH1A1 (0.40) | APPALDH1A1MAOAMAOBKDM4E | |
| SCHEMBL2646823 | 0.72 | CYP4F2 (0.54) | ALDH1A1KDM4ECYP4F2CYP4A11SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4076423-A1 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087440-A | TRPML modulators | 卡斯玛治疗公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | APP 2651/4885ALDH1A1 3737/4885TRPA1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.